Research

Hormonal

Chronic treatment with the beta-3 adrenergic receptor agonist mirabegron (50 mg/day) improves glucose homeostasis, insulin sensitivity, and pancreatic beta-cell function in obese, insulin-resistant humans without causing weight loss or brown adipose tissue activation.

For obese, insulin-resistant individuals, taking 50 mg of mirabegron daily for 12 weeks can significantly improve how the body processes glucose and insulin sensitivity, even without weight loss or the presence of brown fat. This suggests that targeting specific fat tissue receptors can improve metabolic health independently of weight change.

GoodSupportsHIGH confidence
Mirabegron treatment substantially improved multiple measures of glucose homeostasis in obese, insulin-resistant humans... Mirabegron treatment did not significantly change plasma lipid levels... nor did it change... body weight... Mirabegron treatment significantly increased both the insulinogenic index... and the disposition index... indicating improved beta cell function.
Brian S. Finlin et al. · Journal of Clinical Investigation · 2020

Why this rating

Randomized controlled trial in humans with objective metabolic measures (clamps, OGTT) and tissue biopsies, though sample size is small (n=13).

Source

The β3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans

Brian S. Finlin et al. · Journal of Clinical Investigation · 2020

DOI 10.1172/jci134892

rct · n=67Cited 257×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →